ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

ADMA Biologics reports peer-reviewed data showing low thrombosis risk in its IVIG products.

What the company is saying

ADMA Biologics is highlighting the publication of new peer-reviewed data in Frontiers in Cardiovascular Medicine, emphasizing the effectiveness of its further optimized, FDA-licensed IVIG manufacturing process in removing impurities associated with thrombotic risk. The company frames the announcement around analytical results from three commercial-scale lots, stressing that all measured procoagulant and product-related impurities, including Factor XIa, IgA, IgM, cholesterol, and prekallikrein activator, were at or below quantification limits. ADMA underscores that two of three lots had Factor XIa below the limit of quantification and that average non-activated partial thromboplastin time (NAPTT) exceeded 250 seconds, a marker of very low procoagulant activity. The absence of reported thromboembolic events (TEEs) from July 1, 2025 through July 31, 2026 is a central claim. CEO Adam Grossman and Dr. Maeve O’Connor, a recognized immunology leader, are quoted to reinforce the credibility and clinical relevance of the findings. The company acknowledges study limitations, including the small number of lots and limited surveillance period, but maintains a confident tone about the differentiated safety and quality profile of its IVIG portfolio.

What the data suggests

The disclosed data show that all evaluated procoagulant and product-related impurities in three commercial-scale lots of ADMA's IVIG products were at or below quantification limits, with two lots having Factor XIa below the limit of quantification. The average NAPTT exceeded 250 seconds, well above the 200-second threshold associated with reduced TEE risk, indicating very low procoagulant activity. Chromatographic testing found no immunoglobulin aggregates or fragments. No TEEs were reported for ADMA IVIG products manufactured with the optimized process during the 13-month postmarketing surveillance period ending July 31, 2026. The announcement does not provide quantitative data on the increase in immunoglobulin yield or direct comparative figures for product quality or IgG integrity. The results are based on a small sample size and a relatively short observation window, which limits generalizability. The absence of TEEs is encouraging but does not establish causality or rule out risk, as acknowledged by the company and external experts.

Analysis

The announcement is largely factual and focused on realised, measurable outcomes: peer-reviewed publication, analytical testing of three commercial-scale lots, and a year of postmarketing surveillance with no reported thromboembolic events. The only forward-looking claim is a general statement about the company's commitment and belief in its differentiated quality profile, which is clearly aspirational but not central to the release. There is no evidence of exaggerated language or narrative inflation; the results are presented with appropriate scientific context and limitations (e.g., small sample size, limited surveillance period). No large capital outlay or long-dated, uncertain returns are discussed. However, the absence of any financial or profitability metrics means the maximum allowable true_signal is weak_positive, as investors cannot assess the impact on value creation. The data supports operational and product quality improvements, but not financial performance.

Risk flags

• ●The analytical results are based on only three commercial-scale lots, which limits statistical power and may not capture batch-to-batch variability or rare impurity spikes. This small sample size reduces confidence in generalizing findings to all future production.
• ●The postmarketing surveillance period is relatively short (13 months), which may not be sufficient to detect rare adverse events such as thromboembolic events. Underreporting in spontaneous adverse-event systems further weakens the ability to draw definitive safety conclusions.
• ●Thrombosis remains a labeled risk for all IVIG products, including ASCENIV and BIVIGAM, regardless of manufacturing improvements. The absence of reported TEEs in this period does not eliminate the underlying risk for patients.
• ●No quantitative data on the magnitude of immunoglobulin yield increase or direct quality comparisons are disclosed, making it difficult to assess the operational or financial impact of the optimized process.

Bottom line

ADMA Biologics provides credible, peer-reviewed evidence that its optimized IVIG manufacturing process effectively removes key impurities and is associated with very low procoagulant activity, with no reported thromboembolic events over a 13-month period. The data are robust for the three lots tested, but the small sample size and limited surveillance window mean the findings are not yet broadly generalizable. The company is transparent about these limitations, and the involvement of recognized clinical experts adds credibility. No financial or yield improvement figures are disclosed, so the impact on profitability or market share cannot be assessed from this release. Investors should view this as a positive operational and safety update, but broader validation and financial data would be needed for a stronger investment thesis. The most important takeaway is that ADMA’s IVIG products, as currently manufactured, demonstrate a favorable safety profile in recent commercial lots.

Announcement summary

(NASDAQ:ADMA) ADMA Biologics, Inc. announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine presenting new data from its optimized, proprietary intravenous immune globulin (IVIG) manufacturing process. The article, titled “Further Optimization of an ADMA Biologics’ Proprietary Manufacturing Process to Ensure Removal of Impurities Associated With Thrombosis Risk in IVIG Products,” details analytical testing results from three commercial-scale lots of ADMA’s IVIG products manufactured using its FDA-licensed further optimized process. All evaluated procoagulant and product-related impurities, including Factor XIa, IgA, IgM, cholesterol, and prekallikrein activator, were measured at or below applicable quantification limits across the three lots tested. Two of the three lots had Factor XIa levels below the limit of quantification. The three lots demonstrated an average non-activated partial thromboplastin time (NAPTT) exceeding 250 seconds, indicating very low procoagulant activity. Chromatographic testing detected no immunoglobulin aggregates or fragments. The optimized process increased immunoglobulin yield while maintaining product quality and IgG integrity. ADMA’s postmarketing pharmacovigilance surveillance and the FDA Adverse Event Reporting System received no reports of thromboembolic events (TEEs) associated with ADMA IVIG products manufactured using the further optimized process from July 1, 2025 through July 31, 2026. Adam Grossman, President and Chief Executive Officer of ADMA, stated that the findings demonstrate the capabilities of ADMA’s proprietary manufacturing platform to remove impurities associated with thrombotic risk while maintaining immunoglobulin quality and increasing IgG recovery. Dr. Maeve O’Connor, Chief Medical Officer, Consortium of Independent Immunology Clinics (CIIC) & CEO and Medical Director, Integrative Allergy and Immunology Care, commented that the very low procoagulant activity observed, effective removal of Factor XIa and other impurities, and absence of reported thromboembolic events provide reassuring evidence regarding the quality and safety profile of IVIG produced using ADMA’s further optimized manufacturing process. The results should be considered in the context of the study’s limitations, including the evaluation of three manufacturing lots and the relatively limited postmarketing surveillance period. Thrombosis remains a labeled risk for all IVIG products, including ASCENIV™ and BIVIGAM®. ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin approved by the FDA in April 2019 for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients (2 years of age and older). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. BIVIGAM (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin approved by the FDA in May 2019 for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients (2 years of age and older), including X-linked and congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency. The most common adverse reactions to BIVIGAM (reported in ≥5% of clinical study subjects) were headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®. ADMA is also developing SG-001, a pre-clinical investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S.

Disagree with this article?